Yelp Inc (YELP) Sees Above-Consensus Revenue; Potential Mega-Deal Boosts Versartis (VSAR)


Yelp Inc. (NYSE:YELP) shares soared more than 11% to touch a new 52-week high in after-hours trading Tuesday as the company delivered in its financial results quarterly profit and revenue numbers above Wall Street analysts’ forecasts.

For the second quarter 2016, Yelp posted net revenue of $173.4 million, a 30% increase year over year, and non-GAAP net income of $12.5 million, or $0.16 per share, compared to non-GAAP net income of $9.4 million, or $0.12 per share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.15 earnings per share on revenues of $169.8 million for the period

According to its business outlook, Yelp expects third quarter 2016 net revenue to be in a range of between $180 million and $184 million, exceeding the Capital IQ Consensus Estimate of $179.59 million in revenue for the next quarter

YELP stock closed at $32.64, up $0.96 (or +3.03%), with a total volume of 5,883,900 shares traded

Yelp Inc., which provides local business review sites, has 67.98M Shares Outstanding. At close on Tuesday, the company had a Market Capitalization of $2.49B and YELP stock one-year range was from $14.53 to $32.90 per share



Shares of Versartis Inc. (Nasdaq:VSAR) climbed over 8% in the extended session Tuesday after the endocrine-focused biopharmaceutical company said that it has entered into a license and supply agreement with Teijin Ltd. to develop and commercialize its long-acting form of recombinant growth hormone somavaratan (VRS-317) in Japan

As part of the deal, Versartis will receive from Teijin a $40 million upfront payment with potential for up to additional $125 million based on the achievement of pre-determined product milestones

VSAR stock finished the regular session in negative territory by 1.26% (or -$0.14) at $10.99, and 56,380 of its shares changed hands during the day

Versartis, which is developing somavaratan (VRS-317) for the treatment of growth hormone deficiency, has 29.54M Shares Outstanding, Market Capitalization (intraday) of $319.21M and VSAR stock 52-week range is between $6.17 and $19.61 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at